Literature DB >> 16061720

Bosentan in inoperable chronic thromboembolic pulmonary hypertension.

R Hughes, P George, J Parameshwar, F Cafferty, J Dunning, N W Morrell, J Pepke-Zaba.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16061720      PMCID： PMC1747478          DOI： 10.1136/thx.2005.046961

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  10 in total

1.  Clinical worsening during long-term follow-up in inoperable chronic thromboembolic pulmonary hypertension.

Authors:  Bastiaan E Scholzel; Martijn C Post; H W Thijs Plokker; Repke J Snijder
Journal:  Lung       Date:  2011-12-08       Impact factor: 2.584

2.  Bosentan: a rapidly expanding role in the management of cardio-thoracic diseases.

Authors:  Shailendra Kapoor
Journal:  Rheumatol Int       Date:  2008-05-24       Impact factor: 2.631

3.  Diagnostic evaluation and management of chronic thromboembolic pulmonary hypertension: a clinical practice guideline.

Authors:  Sanjay Mehta; Doug Helmersen; Steeve Provencher; Naushad Hirani; Fraser D Rubens; Marc De Perrot; Mark Blostein; Kim Boutet; George Chandy; Carole Dennie; John Granton; Paul Hernandez; Andrew M Hirsch; Karen Laframboise; Robert D Levy; Dale Lien; Simon Martel; Gerard Shoemaker; John Swiston; Justin Weinkauf
Journal:  Can Respir J       Date:  2010 Nov-Dec       Impact factor: 2.409

Review 4.  Chronic thromboembolic pulmonary hypertension.

Authors:  H J Reesink; J J Kloek; P Bresser
Journal:  Neth Heart J       Date:  2006-06       Impact factor: 2.380

5.  Long-term efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension.

Authors:  M C Post; H W M Plokker; J C Kelder; R J Snijder
Journal:  Neth Heart J       Date:  2009-09       Impact factor: 2.380

Review 6.  [Thromboembolism and pulmonary hypertension].

Authors:  D Drömann
Journal:  Internist (Berl)       Date:  2009-09       Impact factor: 0.743

7.  Effects of bosentan on peripheral endothelial function in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.

Authors:  Akihiro Hirashiki; Shiro Adachi; Yoshihisa Nakano; Yoshihiro Kamimura; Shigetake Shimokata; Kyosuke Takeshita; Toyoaki Murohara; Takahisa Kondo
Journal:  Pulm Circ       Date:  2016-06       Impact factor: 3.017

8.  Pulmonary thromboendarterectomy after treatment with treprostenil in a chronic thromboembolic pulmonary hypertension patient: a case report.

Authors:  Konstantinos Porpodis; Maria Konoglou; Paul Zarogoulidis; Evangelos Kaimakamis; Theodoros Kontakiotis; Despoina Papakosta; Vasilis Zervas; Nikolaos Katsikogiannis; Nikolaos Courcoutsakis; Alexandros Mitrakas; Panagiotis Touzopoulos; Michael Karanikas; Konstantinos Zarogoulidis; Aikaterini Markopoulou
Journal:  Int J Gen Med       Date:  2011-11-08

9.  Demographic features, BMPR2 status and outcomes in distal chronic thromboembolic pulmonary hypertension.

Authors:  Jay Suntharalingam; Rajiv D Machado; Linda D Sharples; Mark R Toshner; Karen K Sheares; Rodney J Hughes; David P Jenkins; Richard C Trembath; Nicholas W Morrell; Joanna Pepke-Zaba
Journal:  Thorax       Date:  2007-02-07       Impact factor: 9.139

Review 10.  Review of bosentan in the management of pulmonary arterial hypertension.

Authors:  Eli Gabbay; John Fraser; Keith McNeil
Journal:  Vasc Health Risk Manag       Date:  2007
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.